Abstract
Methods:
Indium-111 activity concentrations in human tumor and normal tissue samples were determined at 24, 48 and 120 hr after i.v. injection of 111In-DTPA-D-Phe-1-octreotide. Fourteen patients were included in the study. Seven patients had medullary thyroid carcinoma, four had midgut carcinoid tumors, two had endocrine pancreatic tumors and one had chronic pancreatitis.
Results:
For midgut carcinoids, the tumor-to-blood ratio was 51:220, for medullary thyroid carcinoma 4:39, and for two endocrine pancreatic tumors 6 and 1500. Tumor-to-muscle ratios varied between 1 and 1200 and tumor-to-fat between 2 and 1500 depending on tumor type.
Conclusion:
The sometimes extremely high tumor-to-normal tissue ratios present the possibility for use of radiolabeled octreotide for radiation therapy of somatostatin receptor positive tumors.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Abdominal Neoplasms / diagnostic imaging
-
Adult
-
Aged
-
Carcinoid Tumor / diagnostic imaging
-
Chronic Disease
-
Female
-
Humans
-
Indium Radioisotopes / administration & dosage
-
Indium Radioisotopes / pharmacokinetics*
-
Injections, Intravenous
-
Male
-
Middle Aged
-
Neuroendocrine Tumors / diagnostic imaging*
-
Neuroendocrine Tumors / metabolism
-
Octreotide / administration & dosage
-
Octreotide / analogs & derivatives*
-
Octreotide / pharmacokinetics
-
Pancreatic Neoplasms / diagnostic imaging
-
Pancreatitis / diagnostic imaging
-
Pentetic Acid / administration & dosage
-
Pentetic Acid / analogs & derivatives*
-
Pentetic Acid / pharmacokinetics
-
Radionuclide Imaging
-
Receptors, Somatostatin / metabolism
-
Reference Values
-
Thyroid Neoplasms / diagnostic imaging
Substances
-
Indium Radioisotopes
-
Receptors, Somatostatin
-
SDZ 215-811
-
Pentetic Acid
-
Octreotide